دورية أكاديمية
Development of a Hospital Compounded, Taste-Masked, Temozolomide Oral Suspension and 5-Year Real-Life Experience in Treating Paediatric Patients
| العنوان: | Development of a Hospital Compounded, Taste-Masked, Temozolomide Oral Suspension and 5-Year Real-Life Experience in Treating Paediatric Patients |
|---|---|
| المؤلفون: | Maxime Annereau, Mélanie Hinterlang, Hugues Bienayme, Gilles Vassal, Antoine Pinon, Mathieu Schmitt, Lucas Denis, Caroline Lemarchand, Laurent Martin, François Lemare, Samuel Abbou, Jérémy Bastid, Lionel Tortolano |
| المصدر: | Pharmaceuticals, Vol 15, Iss 5, p 555 (2022) |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine LCC:Pharmacy and materia medica |
| مصطلحات موضوعية: | remozolomide, antineoplastic drugs, pediatric drug, RP-HPLC, stability study, pediatric oncology, Medicine, Pharmacy and materia medica, RS1-441 |
| الوصف: | The development of oral pediatric forms by pharmaceutical companies is still insufficient. In fact, many drugs used in paediatric oncology, such as temozolomide, are not labeled and adapted for paediatric use. Temozolomide (TMZ) is an alkylating agent used as the standard of care for many adult and pediatric brain tumours, such as neuroblastoma, glioblastoma and medulloblastoma. The present study was carried out to propose a suitable and palatable formulation of the oral liquid preparation of TMZ. The suspension is composed of TMZ suspended in SyrSpend SF pH 4, as well as TMZ crystallization stabilizing agents and sweetening agents. To reach this formulation, several taste-masking agents were evaluated. Here, we describe the method of preparation of the formation as well as the monocentric population treated with the formulation over a 5–year period. A 20 mg/mL TMZ suspension was developed. TMZ suspension is stable for 6 weeks, stored between 2 and 8 degrees, protected from light, and compatible with nasogastric tubes. Thirty-eight patients participated in the palatability study and choose cola flavour, and 104 patients were treated in Gustave Roussy with the developed suspension; no unexpected event was reported. To conclude, we propose here a new TMZ liquid formulation which is stable for at least 6 weeks and well-tolerated with extensive feedback. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1424-8247 |
| Relation: | https://www.mdpi.com/1424-8247/15/5/555; https://doaj.org/toc/1424-8247 |
| DOI: | 10.3390/ph15050555 |
| URL الوصول: | https://doaj.org/article/012319936a1f415d825571ee184c0802 |
| رقم الأكسشن: | edsdoj.012319936a1f415d825571ee184c0802 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14248247 |
|---|---|
| DOI: | 10.3390/ph15050555 |